Exciting new developments in the treatment of multicentric Castleman disease

New therapy aspects for myeloid chronic lymphoma

Careers in translational research

New agents in CLL

BETH study: highly effective treatment option for patients with HER2 breast cancer

Initial phase III results of the first trial in newly diagnosed multiple myeloma

Lenalidomide promotes CRBN-mediated ubiquitination and degradation of IKZF1 and IKZF3

Chimeric antigen receptor produces complete responses and long-term persistence in children and adults relapsed, refractory ALL

Final stage II results of the CLL11 trial

Results from the randomised phase III Children’s Oncology Group (COG) trial, AAML0531

In vitro and in vivo assessment of anfibatide, a novel glycoprotein ib antagonist

Study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman’s disease